Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …

Background Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung
disease resulting from exposure to drugs causing inflammation and possibly interstitial …

Background: The presence of emphysema is relatively common in patients with fibrotic
interstitial lung disease. This has been designated combined pulmonary fibrosis and …

Background There is a paucity of data on the natural trajectory of outcomes in survivors of
COVID-19 beyond 2 years after symptom onset, and no evidence exists on the effect of re …

Rationale: Shared symptoms and genetic architecture between coronavirus disease (COVID-
19) and lung fibrosis suggest severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background Information on pulmonary sequelae and pulmonary function 2 years after
recovery from SARS-CoV-2 infection is lacking. Purpose To longitudinally assess changes …

The clinical importance of interstitial lung abnormality (ILA) is increasingly recognized. In
July 2020, the Fleischner Society published a position paper about ILA. The purposes of this …

Background The long-term pulmonary sequelae of COVID-19 is not well known. Purpose To
characterize patterns and rates of improvement of chest CT abnormalities 1 year after …

Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …

Challenges for the effective management of interstitial lung diseases (ILDs) include
difficulties with the early detection of disease, accurate prognostication with baseline data …